Forxiga safety under the microscope: Real-World data from 1,000 patients
NCT ID NCT07210307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracked over 1,000 adults with type 2 diabetes in Vietnam who were prescribed dapagliflozin (Forxiga) as part of routine care. Researchers monitored side effects and serious events over 24 weeks to confirm the drug's safety in real-world use. The goal was to support the drug's continued approval in Vietnam.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (Forxiga)
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HCMC Heart Institute
Ho Chi Minh City, Vietnam